Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
7-Methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
7-Methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine usage and description
7-Methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo[1,2-c]quinazolin-5-amine, also known as MORP, is a novel research chemical that is used in pharmacological studies for its potential therapeutic properties.
MORP is a selective inhibitor of the protein kinase C (PKC) isoform δ, which is involved in various cellular pathways such as cell proliferation, differentiation, and apoptosis. PKCδ has been implicated in various diseases such as cancer, cardiovascular disease, and neurological disorders. Therefore, the development of PKCδ inhibitors has become an active area of research in drug discovery.
MORP has shown promising results in preclinical studies as a potential therapeutic agent for the treatment of cancer and cardiovascular disease. It has been shown to inhibit the growth of cancer cells and reduce the size of tumors in animal models. Additionally, MORP has been shown to reduce the severity of cardiac injury in animal models of heart disease.
The chemical structure of MORP includes a morpholine group, which makes it a basic compound with a pKa of approximately 9.5. It has a molecular weight of 463.56 g/mol and a melting point of 222-224 °C. MORP is soluble in DMSO and ethanol, but insoluble in water.
In conclusion, MORP is a potential therapeutic agent with PKCδ inhibitory properties that can be used for the treatment of cancer and cardiovascular disease. Further research is needed to fully understand its pharmacological properties and potential clinical applications.